Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia
Open Access
- 21 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 34 (8), 2087-2101
- https://doi.org/10.1038/s41375-020-0866-1
Abstract
Therapy resistance in leukemia may be due to cancer cell-intrinsic and/or -extrinsic mechanisms. Mutations within BCR-ABL1, the oncogene giving rise to chronic myeloid leukemia (CML), lead to resistance to tyrosine kinase inhibitors (TKI), and some are associated with clinically more aggressive disease and worse outcome. Using the retroviral transduction/transplantation model of CML and human cell lines we faithfully recapitulate accelerated disease course in TKI resistance. We show in various models, that murine and human imatinib-resistant leukemia cells positive for the oncogene BCR-ABL1T315I differ from BCR-ABL1 native (BCR-ABL1) cells with regards to niche location and specific niche interactions. We implicate a pathway via integrin β3, integrin-linked kinase (ILK) and its role in deposition of the extracellular matrix (ECM) protein fibronectin as causative of these differences. We demonstrate a trend towards a reduced BCR-ABL1T315I+ tumor burden and significantly prolonged survival of mice with BCR-ABL1T315I+ CML treated with fibronectin or an ILK inhibitor in xenogeneic and syngeneic murine transplantation models, respectively. These data suggest that interactions with ECM proteins via the integrin β3/ILK-mediated signaling pathway in BCR-ABL1T315I+ cells differentially and specifically influence leukemia progression. Niche targeting via modulation of the ECM may be a feasible therapeutic approach to consider in this setting.Keywords
This publication has 59 references indexed in Scilit:
- Focal Adhesion Kinase Stabilizes the CytoskeletonBiophysical Journal, 2011
- Integrin‐linked kinase regulates migration and proliferation of human intestinal cells under a fibronectin‐dependent mechanismJournal of Cellular Physiology, 2009
- Live-animal tracking of individual haematopoietic stem/progenitor cells in their nicheNature, 2008
- Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cellsJCI Insight, 2008
- Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutantsProceedings of the National Academy of Sciences, 2006
- Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in miceProceedings of the National Academy of Sciences, 2006
- Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to ImatinibMolecular and Cellular Biology, 2006
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9Nature, 2006
- Tumour stem cells and drug resistanceNature Reviews Cancer, 2005
- Integrin-linked kinase: a cancer therapeutic target unique among its ILKNature Reviews Cancer, 2005